HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a Phase III clinical trial evaluating...
Hence then, the article about significant os benefit with cadonilimab in first line advanced gastric cancer final analysis of compassion 15 presented at esmo 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025 )
Also on site :
- Ageless Jane Seymour Takes Halloween Inspiration From 2 Iconic Roles—Dr. Quinn and ‘James Bond’s’ Solitaire
- Energy markets are adapting to the Iran war as a ‘forever conflict’ while oil producers keep supplies flowing and avoid ‘mutually assured destruction’
- Dow and Small Caps Climb Weekly While Nasdaq Slips on Megacap Earnings Charges